However, in non-PCD bronchiectasis, neutrophil migration appears preserved125, and a trial of a CXCR2 antagonist given orally for 28 days resulted in about a 70% decrease in the percentage of sputum neutrophils, suggesting that CXCR2 ligands were strong drivers of neutrophil accumulation in the lung126. This evidence concerns the gene CXCR2 and bronchiectasis.